 The Drug Amendments of 1962 required manufacturers to prove to the FDA that the drug in question was both safe and effective.In 1966, the division was reorganized to create the Office of New Drugs, which was responsible for reviewing new drug applications and clinical testing of drugs.In 1982, when the beginning of the biotechnology revolution blurred the line between a drug and a biologic, the Bureau of Drugs was merged with the FDA's Bureau of Biologics to form the "National Center for Drugs and Biologics" during an agency-wide reorganization under Commissioner Arthur Hayes.